Protection requirements for a multi-terminal meshed DC grid

Dirk Van Hertem, Mehrdad Ghandhari, Jean-Baptiste Curis, Olivier Despouys, Andrée Marzin

Frontiers in Pharmacology · 2011 · 68 citations · 0 references

DOIFull text

Open access

Concepts

Abstract

Bone resorption and homeostasis is carried out by osteoclasts, whose differentiation and activity are regulated by the RANK/RANKL axis. Our previous studies using a mouse model of joint injury show that joint trauma induces local inflammation followed by bone remodeling. The transcription factor cyclin-dependent kinase 9 (CDK9) is the major regulator of inflammation, as CDK9 inhibitor flavopiridol effectively suppress injury-induced inflammatory response. The objective of this study was to investigate the underlying mechanism through which flavopiridol regulates bone resorption. The effects of CDK9 inhibition, by the specific-inhibitor flavopiridol, on bone resorption were determined <i>in vivo</i> using two distinct and clinically relevant bone remodeling models. The first model involved titanium particle-induced acute osteolysis, and the second model was ovariectomy-induced chronic osteoporosis. The effects and mechanism of CDK9 inhibition on osteoclastogenesis were examined using <i>in vitro</i> culture of bone marrow macrophages (BMMs). Our results indicated that flavopiridol potently suppressed bone resorption in both <i>in vivo</i> bone-remodeling models. In addition, CDK9 inhibition suppressed <i>in vitro</i> osteoclastogenesis of BMM and reduced their expression of osteoclast-specific genes. Finally, we determined that flavopiridol suppressed RANKL signaling pathway via inhibition of p65 phosphorylation and nuclear translocation of NF-κB. Summary, CDK9 is a potential therapeutic target to prevent osteolysis and osteoporosis by flavopiridol treatment.